Insights

WEF Clinical’s Collaboration with Athira Pharma in Advancing ALS Drug ATH-1105

Amyotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative disease that progressively affects motor neurons, leading to muscle weakness, paralysis, and ultimately, death. The search for effective treatments for ALS has been a long and challenging journey for the medical community. However, recent advancements in drug development have brought new hope to patients and their families. […]

WEF Clinical’s Collaborative Effort with Cantacuzino Institute in Anti-Tick-Borne Encephalitis Vaccine Research

Tick-borne encephalitis (TBE) is a severe viral infection that can cause significant neurological damage, leading to long-term health complications. As the incidence of TBE has risen in recent years, especially in Europe, the urgency to develop effective vaccines has become more pronounced. In response to this growing threat, WEF Clinical joined forces with the Cantacuzino […]

Catalyzing the Development of Albrioza for ALS

Understanding ALS and the Need for Treatment Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig’s disease, is a progressive neurodegenerative disease that affects nerve cells and muscle control. As the disease advances, it becomes increasingly difficult to move, speak, eat, and eventually breathe. Despite significant research efforts, there has been a limited number […]

WEF Clinical’s Pivotal Role in the Development of Rilutek: A Landmark Achievement in ALS Treatment

Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig’s disease, is a devastating neurodegenerative disorder that affects nerve cells in the brain and spinal cord. The progressive nature of ALS leads to the gradual deterioration of motor neurons, resulting in the loss of muscle control and, eventually, the ability to speak, eat, move, and […]